Current Funding
| Role in Project | Source of Support | Period Covered | Project Title |
|---|---|---|---|
| JK: PI | NIH NCI RO1 CA246716 | 07/01/2011 – 11/30/2024 | Drug-Free Macromolecular Therapeutics |
| JY: PI | Department of Defense W81WH-20-1-0573 | 07/01/2020 – 06/30/2024 | KT-1 paired with multivalent polymer – anti-PD-L1 polymer-peptide hybrid: A synergistic chemoimmuno therapy for treatment of triple-negative and metastatic breast cancer |
| JK: PI | National Characterization Laboratory | 12/01/2017 – Present | Preclinical evaluation of backbone degradable HPMA copolymer – epirubicin conjugate |
| JY | Huntsman Cancer Institute | 11/01/2023-10/30/2024 | Development of Next Generation Antibody- Plasma Cell Dyscrasia Drug Conjugates for Treatment of Multiple Program Award |
| Y, D. Cross, Co-PIs | Alzheimer Association | 07/01/2022-01/31/2025 | Backbone-Degradable Polymer-Drug Conjugates for Treatment of Alzheimer’s Disease |
| JY, P. Shami, J. Yap, Co-PIs | Huntsman Cancer Institute Hematology Research Program | 06/01/2024-05/31/2025 | A New Antibody Conjugate for the Treatment of Acute Myeloid Leukemia |
Completed Research Support
| Role in Project | Source of Support | Period Covered | Project Title |
|---|---|---|---|
| JY: Co-PI | Huntsman Cancer Institute Project No.: 210303 | 07/01/2020- 06/30/2021 | A novel antibody-drug conjugate for the treatment of multiple myeloma |
| JY | College of Pharmacy Grant | 04/01/2023- 03/31/2024 | Multivalent DR5 Receptor Clustering Agonists For Treatment of Colon Cancer |
| JK, JY: PIs | Bastion Biologics | 04/15/2019 – 01/31/2020 | DR5 targeted nanoconjugates |
| JK: PI | University of Utah Research Instrumentation Fund | 05/01/2019 – 04/30/2020 | A united platform for multimodal physicochemical characterization of macromolecules and bioconjugates |
| JK, JY: PIs | Huntsman Cancer Institute Project No.: 180303 | 07/01/2017 – 06/30/2019 | Albumin-based combination therapeutics for the treatment of B-cell lymphomas |
| JK, JY: PIs | TheraTarget Project No.: 10051449 | 12/01/2018 – 06/30/2019 | Synthesis of KT-1 |
| JK, JY: PIs | University of Utah Research Foundation | 01/01/2018 – 12/31/2018 | Angiopep-2 mediated brain delivery for the treatment of central nervous system lymphoma |
| JK: Mentor | NIH NCI F31 CA203476 | 05/01/2016 – 04/30/2018 | A multimodal imaging strategy for preclinical optimization of anticancer nanomedicines (predoctoral support for C. Radford) |
| JK: PI | Bastion Biologics Project No.: 50503163 | 12/1/16 – 06/30/17 | Rituximab Therapeutics |
| JK: PI | NIH R42 CA156933 | 09/01/14-02/28/2017 | Backbone Degradable Polymer-Drug Conjugates for the Treatment of Ovarian Cancer |
| JK: PI | Huntsman Cancer Institute Seed Grant Award No.: 160305 | 01/01/16-12/31/16 | A New Therapeutic Approach for Lymphoproliferative Disorder |
| JK Co-P.I. ; P.I. P. Shami | Huntsman Cancer Institute Seed Grant Award No.: 160304 | 01/01/16-12/31/16 | Long-Circulating Targeted Nanomedicines for Leukemia Treatment |
| JK: PI | DoD Grant W81XWH-13-1-0160 | 9/13-8/15 | FRET Imaging Trackable Long-Circulating Biodegradable nanomedicines for Ovarian Carcinoma Therapy |
| JK: PI | NIH GM95606 | 7/11-4/15 | Coiled-Coil Based Drug-Free Macromolecular Therapeutics |
| JK: Mentor | NIH F31 CA186237 | 06/14-05/16 | Development of a Coiled-Coil Therapeutic for Non-HodgkinÕs Lymphoma |
| JK: PI | NIH RO1 CA132831 | 4/08-12/13 | Double-Targeted Macromolecular Therapeutics for the Treatment of Prostate Cancer |
| JK: PI | NIH GM69847 | 8/04-7/13 | Bone Targeted Delivery of Anabolic Agents |
| JK: PI | NIH R41 CA156933 | 9/11-2/13 | Backbone Degradable Polymer-Drug Conjugates for the Treatment of Ovarian Cancer |
| JK: PI | State of Utah | 10/11-2/13 | Biodegradable HPMA Copolymer Carriers |
| JK: PI | University of Utah | 1/12-12/12 | Drug-Free Macromolecular Therapeutics |
| JK: PI | NIH CA 51578 | 8/92-4/11 | A Polymeric Drug Delivery System for Cancer Therapy |
| JK: PI | NIH EB005288 | 4/05-1/10 | Hybrid Hydrogels Self-Assembled from Graft Copolymers |
| JK: PI | University of Utah | 1/09-12/10 | Long-circulating polymeric anticancer medicines |
| JK: PI | University of Utah | 11/07-4/09 | Dynamic Hydrogels: Translating Enzyme-Substrate Recognition into Macromolecular Motion |
| JK: U.S. PI | US-Israel Binational Science Foundation | 10/08-9/10 | A New Polymer-Drug Combination Therapy for Targeting Ovarian Cancer |
| JK: PI | DOD W81XWH-04-1-0900 | 9/04-10/07 | Double-Targeted Macromolecular Therapeutics for the Treatment of Ovarian Cancer |
| JK: Co-P.I.; P.I.: R. Lee | MMRF #20-05 | 11/05-11/06 | Development of Novel Targeted Therapy for Multiple Myeloma |
| JK: P.I. | NIH Fogarty Int. Center; TW 006260 | 12/04-11/07 | Immunotherapy for Ovarian Cancer |
| JK: Co – P.I.; P.I.: R.Stewart | NIH GM072875 | 2/05-1/07 | Dynamically Crosslinked Hydrogels |
| JK: PI | NIH CA 88047 | 3/00-2/06 | Targeting to Lymphocytes Mediated by Synthetic Epitopes |
| JK: PI | Industrial | 4/04-3/05 | Bioconjugates |
| JK: PI | NIH EB 00251 | 4/95-12/03 | Degradable Hydrogels for Oral Delivery of Calcitonin |
| JK: PI | Industrial | 5/01-6/03 | Development of a Polymeric Photosensitizer |
| JK: PI | NIH CA 51578-06S1 | 2/98-1/01 | Supplement to: A Polymeric Drug Delivery System for Cancer Therapy |
| JK: PI | NIH DK 39544 | 3/88-11/02 | Bioadhesive Polymer for Treatment of Colon Disease |
| JK: U.S. PI | U.S.-Israel Binational Science Foundation | 11/99-10/02 | Biorecognizable Sugar Polymers for the Local Treatment of Colon CancerÊ |
| JK: PI | NIH Fogarty Int. Res. Award PA-95-011 | 7/98-11/00 | Bioadhesive Polymer Conjugates with Anticancer Activity |
| JK: PI | CBI, Univ. of Utah | 1/98-12/99 | Photo Control of Aggregation Absoption & Biorecognition of Macromolecules |
| JK: PI | University of Utah | 10/97-9/99 | Genetically Engineered Biomaterials |
| JK: Co-P.I.; P.I.: R.Stewart | NSF | 8/98-7/01 | Hybrid Hydrogels with Swelling Transitions Modulated by Protein Domains |
| JK: U.S. PI | CRDF RN1-411 | 10/97-9/99 | Two-Step Targeted Delivery of HPMA Copolymer-Drug Conjugates with Combination Therapy to Human Ovarian Carcinoma |
| JK: PI | University of Utah | 7/98-6/99 | Expansion of Liquid Chromatography Macromolecular Analysis Station |
| JK: PI | NIH GM 08393 | 7/91-6/96 | Physical Properties of Protein and Polynucleotides |
| JK: PI | Industrial | 2/93-10/99 | Polymers for Protein Modification (Formerly: Vitamin B12 Delivery System) |
| JK: PI | University of Utah | 7/96-6/97 | Light Microscopy and Image Analysis Station |
| JK: PI | CBI, Univ. of Utah | 12/96-11/98 | Biomaterials with Predetermined Three-Dimensional Structures |
| JK: PI | Huntsman Cancer Foundation | 7/96-6/97 | Accumulation and Distribution of Polymer-Adriamycin Conjugates in Solid Tumors |
| JK: PI | CBI, Univ. of Utah | 12/95-12/96 | Photochemical Modification of Biomaterial Surfaces |
| JK: PI | University of Utah | 7/94-6/95 | Bioconjugate Absolute Molecular Weigh Detection System |
| JK: PI | Univ. of Utah Res. Foundation | 7/94-6/96 | PolymericAnticancer Drugs for Treatment of Multidrug Resistant Cells |
| JK: Co-P.I.; P.I.: C. Konak | US-Czech Program | 8/94-7/97 | New Family of Amphiphilic Polymers |
| JK: Co-Inv.; P.I.: P.Kopeckova | Industrial | 1/96-5/97 | Evaluation of Hydrophilic Taxol Derivatives |
| JK: PI | Industrial | 8/93-5/94 | Targeting of Macromolecular Prodrugs to B Lymphocytes |
| JK: PI | CBI, Univ. of Utah | 12/92-11/93 | Light Controlled Adsorption of Macromolecules |
| JK: PI | Industrial | 7/90-6/93 | Insulin Absorption |
| JK: PI | CONRAD | 11/90-6/91 | Synthetic Vaccines |
| JK: PI | University of Utah | 7/90-6/91 | DIONEX BioLC Chromatography System |
| JK: Co-Inv.; P.I.: J. Andrade | Army Research Office | 10/89-9/91 | Regulation of Receptor Binding |
| JK: Co-P.I.; P.I.: S.W. Kim | State of Utah Centers of Excellence | 4/89-6/93 | Center for Controlled Chemical Delivery |
| JK: PI | CBI, Univ. of Utah | 5/90-12/91 | Activation of Proenzymes Adsorbed at Solid-Liquid Interfaces |
| JK: PI | University Research Committee | 11/89-10/90 | Optically Controlled Ligand Delivery |
| JK: PI | College Research Committee | 8/89-7/90 | The Potential of Brush Border Enzymes in Oral Drug Delivery |
| JK: PI | Industrial | 2/89-6/90 | Protein Delivery to the Colon |